// App-Quantinova.ai

3600 : A phase II, randomized, double blind comparison of calcium aluminosilicate clay (CASAD) versus placebo (dibasic calcium carbonate) for the prevention of diarrhea in patients (pts) with metastatic colorectal cancer (mCRC) treated with irinotecan (I).

Researchers

Presenter

  • Bryan K. Kee

Principal Investigators

  • Rebecca Slack

  • Todd S. Crocenzi

  • Lucas Wong

  • Benjamin Esparaz

  • Michael J. Overman

  • Katrina Y. Glover

  • Jeffrey Morris

  • Michael Fisch

Medical Centers

  • White Cancer Research Institute, Temple, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Providence Cancer Center, Portland, OR

  • Tyler Hematology Concology, Tyler, TX

  • Cancer Care Specialists of Illinois, Decatur, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Irinotecan

  • MK8970

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT00748215

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved